2月27日的资金流向数据方面，主力资金净流出1.13万元，占总成交额0.02%，游资资金净流出215.25万 元，占总成交额2.96%，散户资金净流入216.38万元，占总成交额2.98%。 该股主要指标及行业内排名如下： 证券之星消息，截至2026年2月27日收盘，开立医疗(300633)报收于27.09元，上涨1.35%，换手率 0.62%，成交量2.69万手，成交额7260.6万元。 近5日资金流向一览见下表： 该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019 ...

该股主要指标及行业内排名如下： 证券之星消息，截至2026年2月25日收盘，开立医疗(300633)报收于26.98元，上涨1.35%，换手率 0.7%，成交量3.03万手，成交额8182.98万元。 2月25日的资金流向数据方面，主力资金净流出247.16万元，占总成交额3.02%，游资资金净流入592.66 万元，占总成交额7.24%，散户资金净流出345.5万元，占总成交额4.22%。 近5日资金流向一览见下表： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有4家机构给出 ...

证券之星消息，截至2026年2月24日收盘，开立医疗(300633)报收于26.62元，上涨0.08%，换手率 0.62%，成交量2.7万手，成交额7246.33万元。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额 ...

近5日资金流向一览见下表： 证券之星消息，截至2026年2月12日收盘，开立医疗(300633)报收于26.88元，上涨0.3%，换手率0.6%， 成交量2.6万手，成交额6960.7万元。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 2月12日的资金流向数据方面，主力资金净流入183.14万元，占总成交额2.63%，游资资金净流出571.2 万元，占总成交额8.21%，散户资金净流入388.07万元，占总成交额5.58%。 该股主要指标及行业内排名如下： 资金流向名词解释：指通过价格变化反推资 ...

证券之星消息，截至2026年2月11日收盘，开立医疗(300633)报收于26.8元，下跌1.29%，换手率 0.75%，成交量3.23万手，成交额8727.49万元。 2月11日的资金流向数据方面，主力资金净流入109.89万元，占总成交额1.26%，游资资金净流入826.22 万元，占总成交额9.47%，散户资金净流出936.11万元，占总成交额10.73%。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 近5日资金流向一览见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股主要指标及行业内排名如下： 该股最近90天内共有4家机构给出评级，买入评级3家，增持评级1家。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、 ...

Core Viewpoint - The stock of Kaili Medical (300633) has shown a slight increase in price, with recent trading data indicating mixed capital flows among different investor categories [1][2]. Group 1: Stock Performance and Trading Data - As of February 9, 2026, Kaili Medical's stock closed at 27.39 yuan, up by 0.88%, with a turnover rate of 0.52% and a trading volume of 22,400 lots, amounting to 61.21 million yuan [1]. - On February 9, the net inflow of main funds was 2.21 million yuan, accounting for 3.61% of the total trading volume, while retail investors experienced a net outflow of 4.74 million yuan, representing 7.74% of the total [1]. - Over the past five days, the stock has seen fluctuations in capital flows, with notable net inflows and outflows from different investor categories [1]. Group 2: Company Financial Metrics and Industry Comparison - Kaili Medical's total market capitalization is 11.85 billion yuan, which is above the industry average of 11.08 billion yuan, ranking 30th out of 129 companies in the medical device sector [2]. - The company reported a net profit of 33.51 million yuan, significantly lower than the industry average of 207 million yuan, ranking 77th in the industry [2]. - The company's price-to-earnings ratio stands at 265.26, which is considerably higher than the industry average of 89.2, ranking 91st [2]. - Kaili Medical's gross margin is 60.36%, which exceeds the industry average of 50.16%, ranking 51st [2]. - The company reported a debt ratio of 24.22% and a return on equity (ROE) of 1.07%, which is higher than the industry average of 0.41%, ranking 87th [2]. Group 3: Analyst Ratings - In the last 90 days, five institutions have provided ratings for Kaili Medical, with four giving a "buy" rating and one an "accumulate" rating [3].

证券之星消息，截至2026年2月5日收盘，开立医疗(300633)报收于27.27元，下跌0.15%，换手率 0.58%，成交量2.5万手，成交额6820.07万元。 2月5日的资金流向数据方面，主力资金净流入18.45万元，占总成交额0.27%，游资资金净流入631.54万 元，占总成交额9.26%，散户资金净流出649.99万元，占总成交额9.53%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 资金流向名词解释：指通过价格变化反推 ...

证券之星消息，截至2026年2月4日收盘，开立医疗(300633)报收于27.31元，下跌0.51%，换手率 0.77%，成交量3.32万手，成交额9028.36万元。 2月4日的资金流向数据方面，主力资金净流入55.4万元，占总成交额0.61%，游资资金净流入669.87万 元，占总成交额7.42%，散户资金净流出725.27万元，占总成交额8.03%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有5家机构给出评级 ...

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kaili Medical (300633), indicating a decline in stock price and mixed financial results [1][2]. - As of February 2, 2026, Kaili Medical's stock closed at 27.16 yuan, down 2.13%, with a trading volume of 37,100 hands and a total transaction amount of 102 million yuan [1]. - The company's main business involves the independent research, production, and sales of medical diagnostic and treatment equipment [2]. Group 2 - In the third quarter of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, a year-on-year increase of 4.37%, while the net profit attributable to shareholders decreased by 69.25% to 33.51 million yuan [2]. - The third quarter also saw a single-quarter main revenue of 495 million yuan, reflecting a year-on-year increase of 28.42%, but a net profit of -13.52 million yuan, which is an increase of 78.05% compared to the previous year [2]. - The company has a debt ratio of 24.22%, with an investment income of 2.08 million yuan and financial expenses of -38.30 million yuan, while maintaining a gross profit margin of 60.36% [2]. Group 3 - Over the last 90 days, five institutions have provided ratings for Kaili Medical, with four buy ratings and one hold rating [3]. - The article explains the concept of fund flow, indicating that the net flow of funds is determined by the difference between buying and selling pressures in the market [3].

Core Viewpoint - The financial performance of Kaili Medical (300633) shows mixed results, with revenue growth but significant declines in net profit, indicating potential challenges ahead for the company [2]. Group 1: Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, up 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Group 2: Market Activity - As of January 30, 2026, Kaili Medical's stock closed at 27.75 yuan, reflecting an increase of 0.65% [1]. - The turnover rate was 0.87%, with a trading volume of 37,600 hands and a transaction amount of 104 million yuan [1]. - On January 30, the net inflow of main funds was 2.97 million yuan, accounting for 2.85% of the total transaction amount [1]. - Retail investors experienced a net outflow of 2.17 million yuan, representing 2.08% of the total transaction amount [1]. - Over the past 90 days, 8 institutions have provided ratings for the stock, with 6 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 37.0 yuan [2].